Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX11 (Pertuzumab Biosimilar) vs Perjeta in HER2+ Breast Cancer
NCT05346224Phase 3Active, not recruiting
- Sponsor
- Henlius
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by Henlius. Primary endpoint: Total Pathological Complete Response. Started Apr 2022; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05346224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346224.